An Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC Who Failed Either Abiraterone or Enzalutamide
Latest Information Update: 14 Feb 2024
Price :
$35 *
At a glance
- Drugs Pruxelutamide (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Suzhou Kintor Pharmaceuticals
- 11 Dec 2023 Status changed from recruiting to completed.
- 13 Sep 2022 Planned End Date changed from 1 Jun 2022 to 1 Oct 2022.
- 06 Jan 2022 Planned primary completion date changed from 11 Dec 2021 to 31 Mar 2022.